187 related articles for article (PubMed ID: 30214190)
21. Epidermal growth factor receptor targeted methotrexate and small interfering RNA co-delivery.
Steinborn B; Truebenbach I; Morys S; Lächelt U; Wagner E; Zhang W
J Gene Med; 2018 Jul; 20(7-8):e3041. PubMed ID: 29949222
[TBL] [Abstract][Full Text] [Related]
22. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
[TBL] [Abstract][Full Text] [Related]
23. Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line.
Siahmansouri H; Somi MH; Babaloo Z; Baradaran B; Jadidi-Niaragh F; Atyabi F; Mohammadi H; Ahmadi M; Yousefi M
J Pharm Pharmacol; 2016 Sep; 68(9):1119-30. PubMed ID: 27350211
[TBL] [Abstract][Full Text] [Related]
24. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
[TBL] [Abstract][Full Text] [Related]
25. Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo.
Alexander-Bryant AA; Zhang H; Attaway CC; Pugh W; Eggart L; Sansevere RM; Andino LM; Dinh L; Cantini LP; Jakymiw A
Oral Oncol; 2017 Sep; 72():123-131. PubMed ID: 28797448
[TBL] [Abstract][Full Text] [Related]
26. Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice.
Lee SJ; Yhee JY; Kim SH; Kwon IC; Kim K
J Control Release; 2013 Nov; 172(1):358-366. PubMed ID: 24036198
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
28. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
[TBL] [Abstract][Full Text] [Related]
29. Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles.
Wang L; Hao Y; Li H; Zhao Y; Meng D; Li D; Shi J; Zhang H; Zhang Z; Zhang Y
J Drug Target; 2015; 23(9):832-46. PubMed ID: 25856302
[TBL] [Abstract][Full Text] [Related]
30. Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models.
Nascimento AV; Gattacceca F; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Nanomedicine (Lond); 2016 Apr; 11(7):767-81. PubMed ID: 26980454
[TBL] [Abstract][Full Text] [Related]
31. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
32. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
[TBL] [Abstract][Full Text] [Related]
33. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
34. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
Pirollo KF; Rait A; Zhou Q; Hwang SH; Dagata JA; Zon G; Hogrefe RI; Palchik G; Chang EH
Cancer Res; 2007 Apr; 67(7):2938-43. PubMed ID: 17409398
[TBL] [Abstract][Full Text] [Related]
35. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
[No Abstract] [Full Text] [Related]
36. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.
Wang Y; Xu Z; Guo S; Zhang L; Sharma A; Robertson GP; Huang L
Mol Ther; 2013 Oct; 21(10):1919-29. PubMed ID: 23774794
[TBL] [Abstract][Full Text] [Related]
37. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system.
Beale G; Hollins AJ; Benboubetra M; Sohail M; Fox SP; Benter I; Akhtar S
J Drug Target; 2003 Aug; 11(7):449-56. PubMed ID: 15203934
[TBL] [Abstract][Full Text] [Related]
38. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
39. siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells.
Niu J; Li XN; Qian H; Han Z
J Cancer Res Clin Oncol; 2008 Apr; 134(4):503-13. PubMed ID: 17901981
[TBL] [Abstract][Full Text] [Related]
40. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes.
Gao J; Liu W; Xia Y; Li W; Sun J; Chen H; Li B; Zhang D; Qian W; Meng Y; Deng L; Wang H; Chen J; Guo Y
Biomaterials; 2011 May; 32(13):3459-70. PubMed ID: 21296406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]